等待开盘 11-17 09:30:00 美东时间
+0.440
+0.58%
今日重点评级关注:Guggenheim:维持InflaRx"买入"评级,目标价从10美元升至22美元;巴克莱:维持Tandem糖尿病护理"超配"评级,目标价从51美元升至55美元
11-11 10:49
今日重点评级关注:HC Wainwright & Co.:维持Adicet Bio"买入"评级,目标价从4美元升至9美元;Citizens: 维持Rapport Therapeutics"跑赢大市"评级,目标价从77美元升至80美元
11-10 17:17
今日重点评级关注:HC Wainwright & Co.:维持Adicet Bio"买入"评级,目标价从4美元升至9美元;Citizens: 维持Rapport Therapeutics"跑赢大市"评级,目标价从77美元升至80美元
11-10 10:22
<span style="color:#999999;">编者按:聚焦公司高管观点与展望,深挖业绩背后的信息,助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Solventum业绩会实录,以下是财务业绩回顾摘要: ## 1. 财务业绩 **营收表现:** - MedSurg业务(最大业务板块):销售额12亿美元,有机增长1.1% - 整体定价策略:维持在预期的±1%范围内 - SKU合理化项目:对季度业绩产生60个基点的影响 **盈利能力:** - 毛利率:55.8% - 运营费用:7.39亿美元,较上期增加300万美元 **现金流状况:** - 自由现金流:较上期减少2200万美元 - 年度自由现金流指引:在4.5-5.5亿美元目标范围内(剔除P&F剥离影响) ## 2. 财务指标变化 **成本结构
11-08 12:33
Solventum shares are trading higher after the company reported a Q3 earnings be...
11-08 01:49
Piper Sandler analyst Jason Bednar maintains Solventum (NYSE:SOLV) with a Overweight and raises the price target from $94 to $98.
11-07 20:46
Solventum (NYSE:SOLV) raises FY2025 Adj EPS guidance from $5.80-$5.95 to $5.98-$6.08 vs $5.95 analyst estimate..
11-07 05:19
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
11-06 19:12
Jiuzi Holdings, Inc. (NASDAQ:JZXN, ", the Company", ))) today announced it has entered into a Strategic Cooperation Agreement with the SOLV Foundation, a cross-chain Bitcoin staking and structured finance platform
10-27 19:21